Drug Trial Radar · NCT01547091
Safety and Efficacy Study of Umbilical Cord-Derived Mesenchymal Stem Cells for Rheumatoid Arthritis
Last checked: Nov 19, 2026Latest source record: Jun 27, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
200
Planned (sponsor's estimate)
Start
Apr 2013
Primary completion
Oct 2014
Study completion Dec 2014
Sponsor
- Lead sponsor
- Alliancells Bioscience Corporation LimitedIndustry
- Sponsor type
- Industry
- First posted
- Mar 7, 2012
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Rheumatoid arthritis is a chronic systemic disease, which is characterized by chronic inflammation in the synovial tissue. Rheumatoid arthritis will eventually result in the destruction of cartilage, bone and ligaments and joint deformity. The underlying hypothesis is that umbilical cord-derived mesenchymal stem cell (UC-MSCs) has anti-inflammatory effects and thus potentially alleviates the progression of rheumatoid arthritis. The study is to explore the safety and efficacy of UC-MSCs transplantation in treatment of rheumatoid arthritis.
Conditions
- Rheumatoid Arthritis
Interventions
Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs)Biological
-The UC-MSCs will be infused intravenously(single dose, 4x10\^7 cells).The interval time is 3 months, and the study lasts for 12 months with 4 times infusion.
Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs)Drug
-Patients will be treated by conventional drugs (DMARDS) for alleviating disease.
UC-MSC+DMARDSBiological
The UC-MSCs will be infused intravenously(single dose, 4x10\^7 cells).The interval time is 3 months, and the study lasts for 12 months with 4 times infusion.Meanwhile,patients will be treated by conventionally drugs if the disease is still not alleviated.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of MSC treatment.Time frame: six months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The 323 Hospital of Chinese People's Liberation Army
Xi'an, Shaanxi, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.